Hospital-acquired infections from vancomycin-resistant enterococci represent one of medicine's most pressing challenges, with limited treatment options and high mortality rates. Traditional broad-spectrum approaches often devastate beneficial gut bacteria while failing to eliminate these resilient pathogens. A targeted biological solution may now offer a more precise alternative. Scientists have identified a single antibiotic-susceptible Enterococcus strain, E. faecalis X98, that selectively displaces vancomycin-resistant enterococci through direct competitive antagonism. In laboratory cultures and mouse colonization experiments, this lone bacterial warrior significantly reduced VRE populations where multi-strain cocktails failed due to internal competition conflicts. The research team also engineered enhanced versions through controlled phage exposure, creating variants that secrete VRE-killing compounds and carry protective prophage integrations with specific glycosyltransferase mutations. This represents a paradigm shift from shotgun microbiome restoration toward precision microbial therapeutics. The intra-species competition approach could preserve broader gut ecosystem stability while specifically targeting resistant pathogens. However, translating these mouse model successes to human clinical applications faces substantial hurdles including regulatory approval pathways for live bacterial therapeutics, potential immune responses, and ensuring long-term colonization stability. The work provides compelling proof-of-concept for evolutionarily-informed therapeutic design, suggesting that harnessing natural bacterial warfare mechanisms may offer more sustainable solutions than traditional antibiotic escalation. If clinical trials validate these findings, this precision approach could transform treatment of multidrug-resistant infections.